Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus single-agent chemotherapy in third-line or later advanced colorectal cancer
ChiCTR2500097884Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib in colorectal cancer (CRC), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: progression-free survival. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500097884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097884.